SCHEMBL5561340

SCHEMBL5561340

CCCCNC(=O)C1c2ccc(N(CC)CC)cc2OC(C(C)C)C(=O)N1Cc1ccc2c(c1)OCO2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 2/20 0.41
MAPT P10636 4/20 0.41
POLB P06746 3/20 0.41
LMNA P02545 3/20 0.41
ALOX12 P18054 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GAA P10253 2/20 0.41
KMT2A Q03164 5/20 0.39
MEN1 O00255 3/20 0.39
NSD2 O96028 1/20 0.39
THRB P10828 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5561761 0.89 ALDH1A1 (0.42) ALDH1A1KDM4EMAPTPOLBLMNA
SCHEMBL5562269 0.87 GAA (0.49) ALDH1A1MAPTPOLBLMNAALOX12
SCHEMBL5561822 0.85 LMNA (0.40) ALDH1A1KDM4EPOLBLMNAKMT2A
SCHEMBL5562246 0.83 KCNA5 (0.40) ALDH1A1MAPTLMNAGAAKMT2A
SCHEMBL5562392 0.83 MAPT (0.47) ALDH1A1MAPTLMNAGAAKMT2A
SCHEMBL5556272 0.79 ALDH1A1 (0.40) ALDH1A1KDM4EMAPTPOLBLMNA
SCHEMBL5555488 0.78 LMNA (0.40) ALDH1A1KDM4EMAPTPOLBLMNA
SCHEMBL5556238 0.77 KCNA5 (0.43) ALDH1A1MAPTLMNAALOX12KMT2A
SCHEMBL5556322 0.77 KMT2A (0.44) ALDH1A1MAPTL3MBTL1GAAKMT2A
SCHEMBL5561344 0.76 NPSR1 (0.36) MAPTLMNAGAAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1631296-B1 2,3,4,5-TETRAHYDROBENZO¬F|¬1,4|OXAZEPINE-5-CARBOXYLIC ACID AMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE HOFFMANN LA ROCHE (CH) 2007-04-25 EP disclosed
US-7060698-B2 Benzoxazepinone derivatives HOFFMANN-LA ROCHE INC. (US) 2006-06-13 US disclosed
US-20040235819-A1 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. HOFFMANN-LA ROCHE INC. 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235819-A1 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. BACE1, BACE2, PSEN1 ALDH1A1 724/4885KDM4E 1168/4885MAPT 318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.